These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

192 related items for PubMed ID: 24464600

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents.
    Holstein A, Plaschke A, Ptak M, Egberts EH, El-Din J, Brockmöller J, Kirchheiner J.
    Br J Clin Pharmacol; 2005 Jul; 60(1):103-6. PubMed ID: 15963101
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Interaction between variants in the CYP2C9 and POR genes and the risk of sulfonylurea-induced hypoglycaemia: A GoDARTS Study.
    Dujic T, Zhou K, Donnelly LA, Leese G, Palmer CNA, Pearson ER.
    Diabetes Obes Metab; 2018 Jan; 20(1):211-214. PubMed ID: 28656666
    [Abstract] [Full Text] [Related]

  • 6. Impact of clinical factors and CYP2C9 variants for the risk of severe sulfonylurea-induced hypoglycemia.
    Holstein A, Hahn M, Patzer O, Seeringer A, Kovacs P, Stingl J.
    Eur J Clin Pharmacol; 2011 May; 67(5):471-6. PubMed ID: 21213107
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Effect of CYP2C9 polymorphisms on prescribed dose and time-to-stable dose of sulfonylureas in primary care patients with Type 2 diabetes mellitus.
    Swen JJ, Wessels JA, Krabben A, Assendelft WJ, Guchelaar HJ.
    Pharmacogenomics; 2010 Nov; 11(11):1517-23. PubMed ID: 21121772
    [Abstract] [Full Text] [Related]

  • 9. The E23K variant of KCNJ11 and the risk for severe sulfonylurea-induced hypoglycemia in patients with type 2 diabetes.
    Holstein A, Hahn M, Stumvoll M, Kovacs P.
    Horm Metab Res; 2009 May; 41(5):387-90. PubMed ID: 19214942
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Loss-of-function CYP2C9 variants improve therapeutic response to sulfonylureas in type 2 diabetes: a Go-DARTS study.
    Zhou K, Donnelly L, Burch L, Tavendale R, Doney AS, Leese G, Hattersley AT, McCarthy MI, Morris AD, Lang CC, Palmer CN, Pearson ER.
    Clin Pharmacol Ther; 2010 Jan; 87(1):52-6. PubMed ID: 19794412
    [Abstract] [Full Text] [Related]

  • 12. ABCC8 polymorphism (Ser1369Ala): influence on severe hypoglycemia due to sulfonylureas.
    Sato R, Watanabe H, Genma R, Takeuchi M, Maekawa M, Nakamura H.
    Pharmacogenomics; 2010 Dec; 11(12):1743-50. PubMed ID: 21142918
    [Abstract] [Full Text] [Related]

  • 13. Pharmacogenetics of hypoglycemia associated with sulfonylurea therapy in usual clinical care.
    Mitchell SL, Leon DAC, Chaugai S, Kawai VK, Levinson RT, Wei WQ, Stein CM.
    Pharmacogenomics J; 2020 Dec; 20(6):831-839. PubMed ID: 32504053
    [Abstract] [Full Text] [Related]

  • 14. Mild hypoglycaemic attacks induced by sulphonylureas related to CYP2C9, CYP2C19 and CYP2C8 polymorphisms in routine clinical setting.
    Gökalp O, Gunes A, Cam H, Cure E, Aydın O, Tamer MN, Scordo MG, Dahl ML.
    Eur J Clin Pharmacol; 2011 Dec; 67(12):1223-9. PubMed ID: 21691805
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Search for Pharmacoepigenetic Correlations in Type 2 Diabetes Under Sulfonylurea Treatment.
    Karaglani M, Ragia G, Panagopoulou M, Balgkouranidou I, Nena E, Kolios G, Papanas N, Manolopoulos VG, Chatzaki E.
    Exp Clin Endocrinol Diabetes; 2019 Apr; 127(4):226-233. PubMed ID: 29396966
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Pharmacogenetics of sulfonylurea: Presence of CYP2C9*2, CYP2C9*3 and a novel allele, CYP2C9*61, in Type 2 diabetes patients under sulfonylurea therapy.
    Muhammad SD, Khan H, Hussain M, Zeb TF, Kumar D, Rahi R, Asif M, Balooch AA.
    Pak J Pharm Sci; 2020 Jul; 33(4(Supplementary)):1771-1777. PubMed ID: 33612460
    [Abstract] [Full Text] [Related]

  • 19. Hypoglycemia in hospitalized patients treated with sulfonylureas.
    Deusenberry CM, Coley KC, Korytkowski MT, Donihi AC.
    Pharmacotherapy; 2012 Jul; 32(7):613-7. PubMed ID: 22570146
    [Abstract] [Full Text] [Related]

  • 20. Hypoglycemia in patients with type 2 diabetes from India and Malaysia treated with sitagliptin or a sulfonylurea during Ramadan: a randomized, pragmatic study.
    Aravind SR, Ismail SB, Balamurugan R, Gupta JB, Wadhwa T, Loh SM, Suryawanshi S, Davies MJ, Girman CJ, Katzeff HL, Radican L, Engel SS, Wolthers T.
    Curr Med Res Opin; 2012 Aug; 28(8):1289-96. PubMed ID: 22738801
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.